AVANIR Pharmaceuticals Invites Investors to its First Quarter Conference Call on Thursday, February 9, 2006
San Diego, January 18, 2005 – Avanir Pharmaceuticals (AMEX: AVN.R) will webcast its quarterly conference call on Thursday, February 9, 2006 at 1:30 p.m.Pacific/ 4:30 p.m. Eastern. The call will be webcast live through Avanir's corporate website at www.avanir.com and will feature Eric Brandt, President and Chief Executive Officer, and Gregory P. Hanson, Vice President and Chief Financial Officer. A press release announcing the first quarter 2006 financial results will be released prior to the conference call the same day.
It is recommended that you go to Avanir's website at least 10 minutes in advance of the webcast to download any applicable software. For those who cannot listen to the live broadcast, the online replay will be available for 90 days, and a phone replay will be available through February 13, 2006, by dialing 800-642-1687 (domestic) and 706-645-9291 (international) and entering the passcode 4490357.
Avanir Pharmaceuticals is focused on developing and commercializing novel therapeutic products for the treatment of chronic diseases. Avanir's product candidates address therapeutic markets that include central nervous system and cardiovascular disorders, inflammation, and infectious diseases. Avanir previously announced positive results in the second of two required Phase III clinical trials of Neurodex™, an investigational new drug for the treatment of pseudobulbar affect. Additionally, Avanir has initiated a Phase III clinical trial for Neurodex as a potential treatment in patients with diabetic neuropathic pain, a second indication for Neurodex. Avanir has active collaborations with two international pharmaceutical companies: Novartis International Pharmaceutical Ltd. for the treatment of inflammatory disease and AstraZeneca for the treatment of cardiovascular disease. The Company's first commercialized product, Abreva®, is marketed in North America by GlaxoSmithKline Consumer Healthcare and is the leading over-the-counter product for the treatment of cold sores. Further information about Avanir can be found at www.avanir.com.
Avanir Pharmaceuticals Contacts:
Patrick O'Brien Patrice Saxon
The information contained in this press release, including any forward-looking statements contained herein, should be reviewed in conjunction with the company's most recent Annual Report on Form 10-K and quarterly report on Form 10-Q and other publicly available information regarding the Company. Copies of such information are available from the company upon request. Such publicly available information sets forth many risks and uncertainties related to the company's business and technology. Forward-looking statements often contain such words like "estimate," "anticipate," "believe," "plan" or "expect". Avanir disclaims any intent or obligation to update these forward-looking statements.
|What do you think?|
|Jan 18, 2006|